MA54276A - Montélukast de traitement de l'ostéoarthrite érosive de la main - Google Patents

Montélukast de traitement de l'ostéoarthrite érosive de la main

Info

Publication number
MA54276A
MA54276A MA054276A MA54276A MA54276A MA 54276 A MA54276 A MA 54276A MA 054276 A MA054276 A MA 054276A MA 54276 A MA54276 A MA 54276A MA 54276 A MA54276 A MA 54276A
Authority
MA
Morocco
Prior art keywords
montelukast
treatment
hand
erosive osteoarthritis
erosive
Prior art date
Application number
MA054276A
Other languages
English (en)
Other versions
MA54276B1 (fr
Inventor
Alonso Fernando García
Faure Jordi Monfort
Massana Jordi Ramentol
Menéndez Nuria Sanz
García José Ángel Sánchez
Milano Josep Verges
De La Torre Marta Vicario
Original Assignee
Mmc Intellectual Property Inst S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mmc Intellectual Property Inst S L filed Critical Mmc Intellectual Property Inst S L
Publication of MA54276A publication Critical patent/MA54276A/fr
Publication of MA54276B1 publication Critical patent/MA54276B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA54276A 2018-11-26 2019-11-25 Montélukast destinée au traitement de l'arthrose de la main MA54276B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382851 2018-11-26
PCT/EP2019/082425 WO2020109230A1 (fr) 2018-11-26 2019-11-25 Montélukast de traitement de l'ostéoarthrite érosive de la main

Publications (2)

Publication Number Publication Date
MA54276A true MA54276A (fr) 2021-10-06
MA54276B1 MA54276B1 (fr) 2023-11-30

Family

ID=64665075

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54276A MA54276B1 (fr) 2018-11-26 2019-11-25 Montélukast destinée au traitement de l'arthrose de la main

Country Status (22)

Country Link
US (1) US12539296B2 (fr)
EP (1) EP3886857B1 (fr)
JP (1) JP7399502B2 (fr)
CN (1) CN113347975B (fr)
AU (1) AU2019386235B2 (fr)
BR (1) BR112021009980A2 (fr)
CA (1) CA3120920C (fr)
DK (1) DK3886857T3 (fr)
ES (1) ES2961390T3 (fr)
FI (1) FI3886857T3 (fr)
HR (1) HRP20231283T1 (fr)
HU (1) HUE063579T2 (fr)
MA (1) MA54276B1 (fr)
MD (1) MD3886857T2 (fr)
MX (1) MX2021006209A (fr)
MY (1) MY203365A (fr)
PL (1) PL3886857T3 (fr)
PT (1) PT3886857T (fr)
RS (1) RS64668B1 (fr)
SI (1) SI3886857T1 (fr)
TW (1) TWI850283B (fr)
WO (1) WO2020109230A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230372324A1 (en) * 2020-10-13 2023-11-23 Diomed Developments Ltd. Gel formulations comprising montelukast
GB2599912B (en) * 2020-10-13 2023-04-19 Diomed Dev Ltd New formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201020085D0 (en) * 2010-11-26 2011-01-12 Xaragen Pharma Ltd Methods and reagents for the treatment of arthritic disorders
CA2931978A1 (fr) 2013-12-02 2015-06-11 Abbvie Inc. Compositions et methodes pour traiter l'arthrose

Also Published As

Publication number Publication date
PT3886857T (pt) 2023-10-25
CN113347975B (zh) 2024-08-30
EP3886857A1 (fr) 2021-10-06
CA3120920C (fr) 2024-01-02
HUE063579T2 (hu) 2024-01-28
TW202038954A (zh) 2020-11-01
TWI850283B (zh) 2024-08-01
JP2022508236A (ja) 2022-01-19
US12539296B2 (en) 2026-02-03
MY203365A (en) 2024-06-26
MD3886857T2 (ro) 2023-12-31
CA3120920A1 (fr) 2020-06-04
US20220047570A1 (en) 2022-02-17
WO2020109230A1 (fr) 2020-06-04
MA54276B1 (fr) 2023-11-30
AU2019386235A1 (en) 2021-07-01
DK3886857T3 (da) 2023-10-09
HRP20231283T1 (hr) 2024-02-02
FI3886857T3 (fi) 2023-10-20
MX2021006209A (es) 2021-08-11
PL3886857T3 (pl) 2024-01-15
AU2019386235B2 (en) 2024-11-21
RS64668B1 (sr) 2023-11-30
BR112021009980A2 (pt) 2021-08-17
ES2961390T3 (es) 2024-03-11
EP3886857B1 (fr) 2023-07-26
JP7399502B2 (ja) 2023-12-18
CN113347975A (zh) 2021-09-03
SI3886857T1 (sl) 2023-12-29

Similar Documents

Publication Publication Date Title
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3893940A4 (fr) Polythérapie pour le traitement de la dystrophie musculaire
EP3600434A4 (fr) Traitement de l'hypertension pulmonaire
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
MA45192A (fr) Traitement d'association
EP3661493A4 (fr) Régimes thérapeutiques pour le traitement de l'hémoglobinurie paroxystique nocturne
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3541408A4 (fr) Compositions et méthodes pour le traitement de l'angiogenèse aberrante
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3443962A4 (fr) Dérivé de quinoline pour le traitement du cancer de l'estomac
EP3735209A4 (fr) Traitement de la progression de la myopie
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3612214A4 (fr) Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie
EP3430400A4 (fr) Schémas posologiques pour le traitement d'infections fongiques
MA45552A (fr) Compositions destinées au traitement de l'amylose